191 related articles for article (PubMed ID: 36595647)
1. The current status of immunotherapy in the treatment of primary advanced and recurrent endometrial cancer.
Fontenot VE; Tewari K
Curr Opin Obstet Gynecol; 2023 Feb; 35(1):34-42. PubMed ID: 36595647
[TBL] [Abstract][Full Text] [Related]
2. Biomarker-driven therapy in endometrial cancer.
Karpel H; Slomovitz B; Coleman RL; Pothuri B
Int J Gynecol Cancer; 2023 Mar; 33(3):343-350. PubMed ID: 36878569
[TBL] [Abstract][Full Text] [Related]
3. Advanced and recurrent endometrial cancer: State of the art and future perspectives.
Tronconi F; Nero C; Giudice E; Salutari V; Musacchio L; Ricci C; Carbone MV; Ghizzoni V; Perri MT; Camarda F; Gentile M; Berardi R; Scambia G; Lorusso D
Crit Rev Oncol Hematol; 2022 Dec; 180():103851. PubMed ID: 36257537
[TBL] [Abstract][Full Text] [Related]
4. Endometrial cancer: Molecular markers and management of advanced stage disease.
Arend RC; Jones BA; Martinez A; Goodfellow P
Gynecol Oncol; 2018 Sep; 150(3):569-580. PubMed ID: 29843906
[TBL] [Abstract][Full Text] [Related]
5. Latest advances in immuno-oncology for endometrial cancer: single-agent and combination regimens.
Richardson M; Chase DM
Curr Opin Obstet Gynecol; 2024 Feb; 36(1):1-8. PubMed ID: 37792525
[TBL] [Abstract][Full Text] [Related]
6. A Review of Immune Checkpoint Blockade Therapy in Endometrial Cancer.
Green AK; Feinberg J; Makker V
Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-7. PubMed ID: 32213091
[TBL] [Abstract][Full Text] [Related]
7. Facts and Hopes in Immunotherapy of Endometrial Cancer.
Marín-Jiménez JA; García-Mulero S; Matías-Guiu X; Piulats JM
Clin Cancer Res; 2022 Nov; 28(22):4849-4860. PubMed ID: 35789264
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint blockades in gynecological cancers: A review of clinical trials.
Peng H; He X; Wang Q
Acta Obstet Gynecol Scand; 2022 Sep; 101(9):941-951. PubMed ID: 35751489
[TBL] [Abstract][Full Text] [Related]
9. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
Madden DL
Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
[TBL] [Abstract][Full Text] [Related]
10. The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma.
Di Dio C; Bogani G; Di Donato V; Cuccu I; Muzii L; Musacchio L; Scambia G; Lorusso D
Gynecol Oncol; 2023 Feb; 169():27-33. PubMed ID: 36493574
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in the treatment of advanced or recurrent endometrial cancer.
Grau-Bejar JF; Farinas-Madrid L; García-Duran C; García-Illescas D; Mazzeo R; Oaknin A
Clin Adv Hematol Oncol; 2024 Apr; 22(3):129-139. PubMed ID: 38588272
[TBL] [Abstract][Full Text] [Related]
12. Changing treatments paradigms and role of immunotherapy in recurrent endometrial cancer.
Chelariu-Raicu A; Mahdi H; Slomovitz BM
Curr Opin Obstet Gynecol; 2022 Feb; 34(1):28-35. PubMed ID: 34967812
[TBL] [Abstract][Full Text] [Related]
13. A Durable Response to Pembrolizumab in a Patient with Uterine Serous Carcinoma and Lynch Syndrome due to the MSH6 Germline Mutation.
T Danley K; Schmitz K; Ghai R; Sclamberg JS; Buckingham LE; Burgess K; Kuzel TM; Usha L
Oncologist; 2021 Oct; 26(10):811-817. PubMed ID: 34018286
[TBL] [Abstract][Full Text] [Related]
14. Incorporating Molecular Diagnostics into Treatment Paradigms for Endometrial Cancer.
Swift BE; Gien LT
Curr Treat Options Oncol; 2022 Aug; 23(8):1121-1134. PubMed ID: 35793055
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitors for recurrent endometrial cancer.
Mutlu L; Harold J; Tymon-Rosario J; Santin AD
Expert Rev Anticancer Ther; 2022 Mar; 22(3):249-258. PubMed ID: 35176955
[TBL] [Abstract][Full Text] [Related]
16. Dostarlimab: A Review.
Costa B; Vale N
Biomolecules; 2022 Jul; 12(8):. PubMed ID: 35892341
[TBL] [Abstract][Full Text] [Related]
17. Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer.
Kasherman L; Ahrari S; Lheureux S
Future Oncol; 2021 Mar; 17(8):877-892. PubMed ID: 33251877
[TBL] [Abstract][Full Text] [Related]
18. Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.
Marth C; Tarnawski R; Tyulyandina A; Pignata S; Gilbert L; Kaen D; Rubio MJ; Frentzas S; Beiner M; Magallanes-Maciel M; Farrelly L; Choi CH; Berger R; Lee C; Vulsteke C; Hasegawa K; Braicu EI; Wu X; McKenzie J; Lee JJ; Makker V
Int J Gynecol Cancer; 2022 Jan; 32(1):93-100. PubMed ID: 34799418
[TBL] [Abstract][Full Text] [Related]
19. Dostarlimab for recurrent mismatch repair-deficient endometrial cancer: A cost-effectiveness study.
Dioun S; Chen L; Melamed A; Gockley A; St Clair CM; Hou JY; Khoury-Collado F; Hur C; Elkin E; Accordino M; Hershman DL; Wright JD
BJOG; 2023 Jan; 130(2):214-221. PubMed ID: 36330672
[TBL] [Abstract][Full Text] [Related]
20. Treatment strategies for endometrial cancer: current practice and perspective.
Lee YC; Lheureux S; Oza AM
Curr Opin Obstet Gynecol; 2017 Feb; 29(1):47-58. PubMed ID: 27941361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
